CheckMate-067
2015
Nivolumab + Ipilimumab vs Monotherapy in Advanced Melanoma
In 945 patients with untreated advanced melanoma, nivolumab + ipilimumab or nivolumab improved overall survival compared with ipilimumab.
Result
Primary endpoint: PFS and OS
Median PFS 11.5 mo (nivo+ipi) vs 6.9 (nivo) vs 2.9 (ipi); HR vs ipi 0.42 (99.5% CI 0.31–0.57, P<0.001) combo, 0.57 (99.5% CI 0.43–0.76, P<0.001) nivo.
- Subtopic
- Advanced melanoma
- Design
- Double-blind RCT, three arms
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Larkin J, et al. N Engl J Med. 2015;373(1):23-34.doi 10.1056/NEJMoa1504030
Discussion & critique
Longest reported median OS in any advanced-melanoma phase-3 trial; foundational benchmark for combination checkpoint blockade. Combination toxicity is substantial.